Zhang, Lianjun
Guo, Wancheng https://orcid.org/0009-0008-8955-3010
Fu, Yu-Hsuan https://orcid.org/0000-0002-5917-2961
Wu, Dijiong https://orcid.org/0000-0003-2338-9365
Li, Man
Chen, Ying-Chieh
Tseng, Chi-Yang
Hua, Wei-Kai
Nguyen, Le Xuan Truong https://orcid.org/0000-0001-5464-0861
He, Xin
Dong, Haojie
Zhang, Lei
Zhang, Bin https://orcid.org/0000-0003-4703-7524
Li, Ling
Marcucci, Guido https://orcid.org/0000-0002-3983-5908
Kuo, Ya-Huei https://orcid.org/0000-0003-2595-0419
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA205247)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA205247)
American Society of Hematology (N/A)
Article History
Received: 24 September 2025
Revised: 10 March 2026
Accepted: 27 March 2026
First Online: 21 April 2026
Competing interests
: Y-HK is a co-inventor on a patent application covering the HDAC8 inhibitor compound and methods.